Treatment of dyslipidemias.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
P H Jones

Abstract

To summarize recommended treatment strategies for various dyslipidemias. The basic pathways of lipoprotein metabolism are reviewed, and the potential for interventional alterations to correct specific dyslipidemias is outlined. Guidelines for treatment based on published clinical trials, including the consensus report of the National Cholesterol Education Program, are discussed. The nonpharmacologic options of diet and exercise are important elements in the treatment of dyslipidemias. In most patients, a reduced dietary intake of fat (particularly saturated fat) should be maintained for 3 months before drug therapy is initiated. The various mechanisms of action of the bile acid resins, niacin, hydroxy-methylglutaryl-coenzyme A reductase inhibitors, and fibric acid derivatives are described, and their roles in monotherapy or combination therapy for hypercholesterolemia, combined hyperlipidemia, and hypertriglyceridemia are examined. With an understanding of the metabolic pathways responsible for the production and removal of lipoproteins and an overview of results of previous pharmacologic interventions, clinicians can optimize lipid-lowering treatment in individual patients with dyslipidemia.

References

Jul 1, 1992·The American Journal of Cardiology·C J GlueckJ Lang
Jan 1, 1991·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M A Austin
Oct 1, 1990·American Journal of Epidemiology·J A Berlin, G A Colditz
Dec 19, 1990·JAMA : the Journal of the American Medical Association·J P KaneR J Havel
Jul 7, 1988·The New England Journal of Medicine·S M Grundy
Jun 19, 1987·JAMA : the Journal of the American Medical Association·D H BlankenhornL Cashin-Hemphill
Apr 4, 1986·Science·M S Brown, J L Goldstein
Apr 6, 1994·JAMA : the Journal of the American Medical Association·E J SchaeferR I Levy
Nov 15, 1993·Annals of Internal Medicine·D H BlankenhornUNKNOWN MARS Research Group
Mar 2, 1994·JAMA : the Journal of the American Medical Association·J M McKenneyV M Chinchili
Jun 14, 1993·Annals of the New York Academy of Sciences·W E ConnorS L Connor
Jan 1, 1993·The American Journal of Medicine·O WiklundS O Olofsson

❮ Previous
Next ❯

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
Anila NisarAbid Zaheer Farooqi
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
T O'Brien
© 2022 Meta ULC. All rights reserved